Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Erlotinib + trametinib
- Development stage
- Phase 2
- Lead developer
- Novartis
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Erlotinib + trametinib is a combination of two small molecule targeted therapies used in clinical research for the treatment of cancers with acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. Erlotinib is an EGFR tyrosine kinase inhibitor that blocks the activity of the epidermal growth factor receptor, thereby inhibiting cancer cell proliferation and survival. Trametinib is a MEK inhibitor that targets mitogen-activated protein kinase kinases 1 and 2 (MEK1/2), components of the MAPK/ERK pathway involved in cell division and survival. The combination has been studied primarily in patients with metastatic EGFR-mutant non-small cell lung cancer (NSCLC) who have developed resistance to prior EGFR TKI therapy[2][8]. The rationale for this combination is to overcome resistance mechanisms by dual inhibition of both EGFR and downstream MEK signaling pathways.
- Other names
- erlotinibtrametinib
02
Targets
EGFR (Epidermal growth factor receptor)MEK1 (Dual specificity mitogen-activated protein kinase kinase 1)MEK2 (Dual specificity mitogen-activated protein kinase kinase 2)
Beyond the preview
Go deeper on Erlotinib + trametinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Erlotinib + trametinib.